Siga technologies inc (SIGA)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Cash and Cash Equivalents, Period Increase (Decrease) [Abstract]
Cash flows from operating activities:
Net (loss)/income

-7,241

421,807

-36,235

-39,697

-39,451

-265,463

-17,177

-14,059

29,099

-50,348

-19,400

Adjustments to reconcile net (loss)/income to net cash provided by operating activities:
Depreciation and other amortization

526

69

132

174

247

351

463

419

568

625

475

(Gain) loss on change in fair value of warrant liability

-5,091

6,922

4,738

894

0

-313

-

-804

-24,436

38,099

7,522

Lease termination

0

0

-1,225

0

0

-

-

-

-

-

-

Stock-based compensation

2,113

2,273

1,101

775

1,574

2,435

2,263

1,779

12,463

1,483

2,141

Net realization of deferred revenue and costs due to FDA approval

0

281,950

0

0

-

-

-

-

-

-

-

Deferred income taxes, net

-2,417

-9,301

-2,718

20

21

53,569

-9,599

-7,847

-36,051

175

0

Write down of inventory, net

0

0

536

0

0

-

-

-

-

-

-

Loss on disposal of assets

-

-

-

-

-243

0

-

-

-

-

-

Non-cash backstop fee

-

-

-

1,764

10

31

48

0

-

-

-

Gain on sale of assets

-

-

-

-

-

345

-

0

-

-

-

Non-cash interest expense

4,497

4,497

4,497

566

0

0

-

-

-

-

-

Gain on sale of priority review voucher

0

78,338

0

0

-

-

-

-

-

-

-

Interest expense on term loan-paid with restricted cash

-

-

-

-

0

0

-

-

-

-

-

Reorganization items

-

-

-

-

-

-

-

0

0

-

-

Changes in assets and liabilities:
Accounts receivable

2,208

49

-1,352

-522

3,185

-490

-3,759

2,104

-365

596

446

Inventory

6,744

-0

-22,690

13,762

-6,597

-1,470

2,873

17,641

0

0

-

Deferred costs

0

0

23,943

19,712

20,075

10,277

19,741

2,591

250

0

-

Prepaid expenses and other assets

714

2,579

1,125

330

-229

236

-188

444

-12

-1,216

192

Other assets

-

-

-

-80

0

-43

-147

548

4

-24

20

Accounts payable, accrued expenses and other liabilities

936

2,045

-2,051

-177

1,862

-4,436

-4,566

7,550

2,659

-125

1,181

Liabilities subject to compromise

-

-

-

-160,072

-192,067

399,039

0

0

-

-

-

Deferred revenue

-1,861

3,475

11,412

112,225

255,176

-162,140

105,170

16,050

41,001

0

0

Other liabilities

-

-

-

-84

-73

-42

281

18

147

-1,379

267

Net cash provided by operating activities

-18,204

68,871

-18,386

-116,813

11,109

14,176

58,436

-20,222

25,574

-10,825

-8,470

Cash flows from investing activities:
Capital expenditures

29

102

100

23

108

28

857

588

237

549

340

Net proceeds from sale of priority review voucher

0

78,338

0

0

-

-

-

-

-

-

-

Proceeds from sale of assets

-

-

-

-

-

569

-

0

-

-

-

Return of collateral for surety bond

-

-

-

1,212

0

0

-

-

-

-

-

Collateral for surety bond

-

-

-

-

-

-

-

1,347

0

0

-

Restricted cash

-

-

-

-

-4,000

4,000

0

0

-

-

-

Proceeds from maturity of short term investments

-

-

-

-

-

-

-

-

40,000

31,250

0

Purchases of short term investments

-

-

-

-

-

-

-

-

25,004

41,235

4,999

Net cash used in investing activities

-29

78,236

-100

1,188

3,891

-3,458

-857

-1,936

14,758

-10,535

-5,340

Cash flows from financing activities:
Payment of employee tax obligations for common stock tendered

1,176

4,074

591

428

0

415

-

0

1,353

-

-

Net proceeds from exercise of stock options

0

261

89

0

12

-

-

-

-

-

-

Net proceeds from exercise of warrants and options

-

-

-

-

-

102

2,868

9

3,946

13,196

7,420

Net proceeds from equity rights offering - net of offering costs

-

-

-

34,596

0

0

-

-

-

-

-

Proceeds from Term Loan escrow release

-

-

-

28,694

-

-

-

-

-

-

-

Proceeds from issuance of securities

-

-

-

-

-

-

-

-

-

-

18,565

Repurchase of common stock

0

0

84

0

0

-

-

-

-

0

0

Debt issue costs

-

-

-

3,775

0

0

-

-

-

-

-

Proceeds from issuance of long-term debt

-

-

-

-

-

-

-

4,910

0

0

-

Repayment of Term Loan

-

-

-

-

2,000

2,000

8,000

0

0

-

-

Excess tax benefit from stock-based compensation

-

-

-

-

15

0

-

-

-

-

-

Excess tax benefit from share-based compensation

-

-

-

-

-

-

-

0

0

-

-

Net cash used in financing activities

-1,176

-3,812

-585

59,087

-2,003

-2,313

1,713

4,919

2,592

13,196

25,985

Net increase (decrease) in cash and cash equivalents

-

-

-

-56,536

12,997

8,404

59,292

-17,239

42,924

-8,164

12,174

Net (decrease)/increase in cash, cash equivalents and restricted cash

-19,409

143,295

-19,072

-

-

-

-

-

-

-

-

Supplemental disclosure of non-cash activities:
Conversion of warrant to common stock

1,172

6,007

0

0

-

-

-

-

-

-

-

Issuance of common stock upon cashless exercise

118

1,681

0

0

-

-

-

-

-

-

-

Portion of Term Loan paid directly to PharmAthene by the Lender in satisfaction of the PharmAthene claim; such liability is part of the Liabilities Subject to Compromise line item

-

-

-

46,900

0

0

-

-

-

-

-

Cash interest paid on PharmAthene liability

-

-

-

11,668

0

0

-

-

-

-

-

Cash interest paid on Term Loan from restricted cash

-

-

-

-

0

0

-

-

-

-

-

Cash income taxes (refund) paid, net

-1,276

251

325

500

-420,029,000

728

-

-

-

-

-

Reclass of common stock warrant liability to additional paid-in capital upon warrant exercise

-

-

-

-

-

751

-

0

9,531

30,555

1,715

Fair value of warrant, at issuance date, in connection with loan agreement and recorded as warrant liability

-

-

-

5,832

0

0

-

-

-

-

-